Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma

Stopped early · Phase 1/Phase 2

Conditions studied: Adult Liposarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma

In brief

RATIONALE: Antiviral drugs, such as nelfinavir mesylate, may help prevent cancer cells from spreading. PURPOSE: This phase I/II trial is studying the side effects and best dose of nelfinavir mesylate and to see how well it works in treating patients with recurrent, metastatic, or unresectable liposarcoma.

Key facts

Study ID

NCT00233948

Run by

City of Hope Medical Center

People needed

29

Starts

2006-03-01

Last updated by the study team

2015-04-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• City of Hope Medical Center — Duarte, California, United States
• South Pasadena Cancer Center — Pasadena, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.